JP7840570B2 - コロナウイルス感染症の処置のための方法 - Google Patents

コロナウイルス感染症の処置のための方法

Info

Publication number
JP7840570B2
JP7840570B2 JP2022561484A JP2022561484A JP7840570B2 JP 7840570 B2 JP7840570 B2 JP 7840570B2 JP 2022561484 A JP2022561484 A JP 2022561484A JP 2022561484 A JP2022561484 A JP 2022561484A JP 7840570 B2 JP7840570 B2 JP 7840570B2
Authority
JP
Japan
Prior art keywords
cov
sars
composition according
probenecid
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022561484A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520929A5 (https=
JPWO2021207606A5 (https=
JP2023520929A (ja
Inventor
ラルフ エー． トリップ，
ジャクリーン マレイ，
ロバート ジェフ ホーガン，
Original Assignee
ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/875,487 external-priority patent/US11116737B1/en
Application filed by ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド filed Critical ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド
Publication of JP2023520929A publication Critical patent/JP2023520929A/ja
Publication of JP2023520929A5 publication Critical patent/JP2023520929A5/ja
Publication of JPWO2021207606A5 publication Critical patent/JPWO2021207606A5/ja
Application granted granted Critical
Publication of JP7840570B2 publication Critical patent/JP7840570B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022561484A 2020-04-10 2021-04-09 コロナウイルス感染症の処置のための方法 Active JP7840570B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063008624P 2020-04-10 2020-04-10
US63/008,624 2020-04-10
US202063023021P 2020-05-11 2020-05-11
US63/023,021 2020-05-11
US16/875,487 2020-05-15
US16/875,487 US11116737B1 (en) 2020-04-10 2020-05-15 Methods of using probenecid for treatment of coronavirus infections
EP20202059.0 2020-10-15
EP20202059.0A EP3892269B1 (en) 2020-04-10 2020-10-15 Probenecid for treating coronavirus infections
US202163151551P 2021-02-19 2021-02-19
US63/151,551 2021-02-19
PCT/US2021/026588 WO2021207606A1 (en) 2020-04-10 2021-04-09 Methods for treatment of coronavirus infections

Publications (4)

Publication Number Publication Date
JP2023520929A JP2023520929A (ja) 2023-05-22
JP2023520929A5 JP2023520929A5 (https=) 2024-04-16
JPWO2021207606A5 JPWO2021207606A5 (https=) 2024-04-16
JP7840570B2 true JP7840570B2 (ja) 2026-04-06

Family

ID=78023981

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022561484A Active JP7840570B2 (ja) 2020-04-10 2021-04-09 コロナウイルス感染症の処置のための方法

Country Status (5)

Country Link
EP (1) EP4132503B1 (https=)
JP (1) JP7840570B2 (https=)
CN (1) CN116075298B (https=)
AU (1) AU2021254262A1 (https=)
WO (1) WO2021207606A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024529291A (ja) * 2021-07-06 2024-08-06 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド ウイルス感染症の処置および予防のための組成物および方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4157288A2 (en) * 2020-06-02 2023-04-05 Institut Gustave-Roussy Modulators of purinergic receptors and related immune checkpoint for treating acute respiratory distress syndrom

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130280806A1 (en) 2010-05-17 2013-10-24 Donald Rubin Mammalian genes involved in infection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005596A2 (en) * 2003-06-18 2005-01-20 Chinese National Human Genome Center At Shanghai Characterization of the earliest stages of the severe acute respiratory syndrome (sars) virus and uses thereof
MX341050B (es) * 2010-04-07 2016-08-05 Celgene Corp * Metodos para tratar infeccion viral respiratoria.
US11554112B2 (en) * 2018-06-07 2023-01-17 Herum Therapeutics International Limited Combinations of β-lactam compounds and probenecid and uses thereof
CN111601618A (zh) * 2018-09-14 2020-08-28 江阴贝瑞森制药有限公司 孟鲁司特与肽的新缀合物
EA202193251A1 (ru) * 2019-06-05 2022-03-10 Эмори Юниверсити Пептидомиметики для лечения коронавирусной и пикорнавирусной инфекций

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130280806A1 (en) 2010-05-17 2013-10-24 Donald Rubin Mammalian genes involved in infection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XORTX Launches XRx-101, A New Program to Treaat Coronavirus COVID-19 Infection.，Biospace.com，2020年03月16日，https://www.biospace.com/article/releases/xortx-launches-xrx-101-a-new-program-to-treat-coronavirus-covid-19-infection/

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024529291A (ja) * 2021-07-06 2024-08-06 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド ウイルス感染症の処置および予防のための組成物および方法

Also Published As

Publication number Publication date
EP4132503A4 (en) 2024-02-14
EP4132503A1 (en) 2023-02-15
WO2021207606A1 (en) 2021-10-14
CA3173187A1 (en) 2021-10-14
CN116075298B (zh) 2026-03-20
CN116075298A (zh) 2023-05-05
EP4132503B1 (en) 2026-04-22
AU2021254262A1 (en) 2022-11-03
JP2023520929A (ja) 2023-05-22

Similar Documents

Publication Publication Date Title
US20210361688A1 (en) System, method and use of a certain medication for reducing viral replication in the airways mucosae
US11364227B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
EP3892269B1 (en) Probenecid for treating coronavirus infections
US20230147683A1 (en) Treatment
CN113244212B (zh) 黄芩素在制备预防和/或治疗新型冠状病毒感染疾病的药物中的应用
JP7840570B2 (ja) コロナウイルス感染症の処置のための方法
US11433080B2 (en) Antiviral treatment
CA3173187C (en) Methods for treatment of coronavirus infections
US20240327339A1 (en) Compositions and methods for treating and preventing viral infections
US12115150B2 (en) Biomarkers of coronavirus pneumonia
RU2842052C1 (ru) Азеластин в качестве противовирусного лечения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240404

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260317

R150 Certificate of patent or registration of utility model

Ref document number: 7840570

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150